Extract

Safety Run-in To determine the MTD for each of the two regimens of AS703026 in subjects with advanced hematological malignancies Phase II To assess the anti-leukemic activity of two regimens of AS703026 in older subjects with newly diagnosed poor prognosis AML, who are not candidates for intensive chemotherapy

Inclusion criteria

• The Safety run-in dose escalation part will be performed in subjects with refractory hematological malignancies and do not have effective standard therapies available. The Phase II part will be performed in older subjects with Poor Prognosis Acute Myeloid Leukemia

Links

• ictrp
• euctr